

Table 5.6a
Immunosuppression Use for Induction, 1998 to 2007
Recipients with Kidney Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	12,452	12,760	13,613	14,266	14,779	15,137	16,004	16,482	17,091	16,623
With Immunosuppression Info	12,334	12,488	13,252	14,120	14,600	14,937	15,733	16,082	16,731	16,114
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	12.2%	6.6%	3.2%	2.5%	1.9%	1.1%	1.8%	1.6%	0.6%	1.1%
OKT3	10.0%	3.9%	1.8%	0.8%	0.9%	0.4%	0.3%	0.4%	1.1%	1.2%
Thymoglobulin	0.2%	4.9%	10.1%	17.1%	25.8%	33.6%	36.6%	38.9%	42.1%	43.8%
Zenapax	13.0%	16.5%	13.1%	14.4%	12.9%	12.5%	11.3%	11.6%	11.3%	10.8%
Simulect	5.0%	17.2%	26.6%	25.3%	26.4%	21.6%	19.0%	16.3%	17.8%	16.6%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	3.6%	6.8%	8.8%	10.3%	9.5%
No Induction Drugs Recorded	61.1%	53.0%	47.7%	42.5%	35.1%	30.2%	27.9%	26.1%	21.3%	22.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.